Entry and Regulation – Evidence from Health Care Professions Prof. Frank Verboven Presentation at DG-Competition 13 December 2006 “The Economic case for.

Slides:



Advertisements
Similar presentations
1 Policy options to address access to chronic disease medicines Dr. Richard Laing Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical.
Advertisements

From POM to P From POM to P Wellard’s NHS training wellards.co.uk 2004.
Do Health Care Regulation and Physician-Industry Interaction Influence Antibiotic Resistance Rates? The Example of Antimicrobial Prescribing and Dispensing.
Managing in the Global Environment chapter six lecture 2 McGraw-Hill/Irwin Copyright © 2011 by The McGraw-Hill Companies, Inc. All rights reserved.
317_L21, Mar 4, 2008, J. Schaafsma 1 Review of the Last Lecture began our discussion of information asymmetry in the healthcare market Two aspects to the.
International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.
1. People can’t have everything they want, so they choose. 2. People make better decisions when they weigh the present and future benefits and costs of.
Presenter: Joseph Reid Paper: The Market for Health Care Date : 6/04/07.
© 2008 Pearson Addison Wesley. All rights reserved Chapter Nine Properties and Applications of the Competitive Model.
EHM Theory and Structure Behavioural Labour Supply Modelling in DWP Alan Duncan, 6 th May 2009.
Congressional Budget Office Presentation to The Tax Policy Center and the American Tax Policy Institute Taxes and Health Insurance February 29, 2008.
FOR AND AGAINST Minimum Wage. Aim The main aim is to reduce poverty and to reduce pay differentials between men and women. Other aims include reducing.
The Pricing Decision and Customer Profitability Analysis
Capacity Task Force Virginia Health Reform Initiative January 14, 2011
Drug Pricing in Canada Victoria Brown, Anureet Sohi, Lisa Weger SPHA 511.
The Effects of De-listing Publicly Funded Health Care Services Mark Stabile Department of Economics and Center for Economics and Public Affairs University.
Supply Side policies AS Economics.
What is the Impact of the Internet on Medical Care Use and Cost? Implications of Value Based Benefit Design from a Consumer Driven Health Plan Stephen.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
Tax Subsidies for Out-of-Pocket Healthcare Costs Jessica Vistnes Agency for Healthcare Research and Quality William Jack Georgetown University Arik Levinson.
Chapter 8 Labor Mobility
Healthcare Reforms and Pharmaceuticals Lessons from Turkey Prof. Dr. Mehtap Tatar Hacettepe University Faculty of Economics and Administrative Sciences.
The fiscal costs of ageing in the euro area: will the young have to pay the bill? Ad van Riet Head of the Fiscal Policies Division European Central Bank.
IDENTIFYING AND SELECTING INTERNATIONAL MARKETS. INTRODUCTION Before making an entry in the international market, a firm has to identify those markets.
The Czech Health System – its Presence and Future Pavel Hroboň L.Dittrich.
The competition between innovative and generic pharmaceutical companies intensified in the last decades. The models created by innovative pharmaceutical.
TBS Seminar on Essential Medicines and Health Products Geneva, 29 October 2013 Matthew Jowett, PhD Senior Health Financing Specialist Dept. Health Systems.
Summary from the Economics Track With thanks to all track participants, presenters, rapporteurs, moderators and organizers.
Margarit MELIKYAN Drug Utilization Research Group PO, Armenia, National Institute of Health Access to and Use of Medicines by Households in Armenia: Impact.
Foreign Market Selection – Managerial Issues
Competitiveness of the European-based Pharmaceutical Industry Prospective of a New Member State Imre Hollo Deputy Secretary of State, MOH Hungary.
AIFA European Conference on Clinical Research for Decision Making Sergio Dompé - Farmindustria Rome, March 30th, 2007 Access to market by new medicines.
The Pricing of Pharmaceuticals facing Grey Imports Toulouse, December 2003 Claude Crampes - Abraham Hollander.
MGMT 510 – Macroeconomics for Managers Presented By: Prof. Dr. Serhan Çiftçioğlu.
1 An Economic and Policy Analysis of the Market for Methylphenidate and Amphetamine Rick Mayes University of Richmond Farasat Bokhari University of California,
Chapter Eight The Political Economy of Foreign Direct Investment.
Ch. 11 General Equilibrium and the Efficiency of Perfect Competition
Market and Command Economies
Strictly confidential How to achieve sustainability in rapidly changing environment? Pavle Marjanović, Country Manager for Actavis Republic of Serbia and.
R&D Investments in Pharmaceutical Markets Abdulkadir Civan Fatih University.
1 Trade related regulations in services sectors - Balkan experiences Nora Dihel OECD Trade Directorate.
The Free Enterprise System Ch. 5. Basic Principles – Free Enterprise System Freedom of Choice Invest Their Money All of These Freedoms are a Part of a.
ECONOMIC SYSTEM COMPONENTS Private Ownership l Control of productive resources land labor capital that are used to produce goods and services.
IGCSE®/O Level Economics
Chapter 2: The Role of Economics
Foreign Market Selection – Managerial Issues
Does Innovation stimulate employment? A firm-level analysis using comparable micro data from four European countries Harrison-Jaumandreu-Mairesse-Peters.
SUPPLY SIDE POLICIES YOUSIF AL ZAROUNI. WHAT ARE SUPPLY SIDE POLICIES? Supply side policies are policies designed to improve the supply side potential.
Journal of Economic Behavior and Organization Presented by: Kuan Chen.
Slides for Class 10: Traditional Economic Model That Depicts a Firm’s Output Problems With the Traditional Model The Implications These Problems Raise.
Health Economics & Policy 3rd Edition James W. Henderson
Unit 2 Entrepreneurship & The Economy. Economics Social science concerned with how people satisfy their demands for goods and services.
Impact of Innovation on Financial Results in the Pharmaceutical Industry Benjamin Jonen Kevin Mabe.
An Economic Perspective
Hospital Pricing Mike Del Trecco, Senior Vice President of Finance, Finance and Operations Senate Finance Committee February 9, 2017.
Economics of Pharmaceutical Regulation in the Mediterranean: the case of Spain and Italy Joan Costa Font LSE.
The Czech Health System – its Presence and Future
Carnegie Mellon University
Canada Needs PAs.
Gary Fournier Economics
Canada Needs PAs.
External Influences on Business
Abstract Impact of the National Healthcare Reform on Prescribing Patterns of Promotional Targeted Drugs among Thai Physicians Layton MR*, Chadbunchachai.
Entry and Regulation – Evidence from Health Care Professions
Canada Needs PAs.
Entry and Regulation – Evidence from the Health Care Professions
Canada Needs PAs.
The incidence of Mandated Maternity Benefits
Canada Needs PAs.
Canada Needs PAs.
Presentation transcript:

Entry and Regulation – Evidence from Health Care Professions Prof. Frank Verboven Presentation at DG-Competition 13 December 2006 “The Economic case for professional services reform”

Background to this study oAcademic research paper oJoint work with Catherine Schaumans, doctoral student at K.U.Leuven oFinanced by K.U.Leuven and Fonds Wetenschappelijk Onderzoek (Flemish Science Foundation)

Health care markets Complicated markets (like many markets …) Demand side: patients need Medical diagnosis Medical treatment, including drugs Supply side Pharmaceutical companies investing in R&D Physicians treating patients Government: broad access to medical care Offer high reimbursement Guarantee sufficient geographical coverage

Implications of high reimbursement policy Agency problem Physician has an incentive to prescribe too many drugs Common solution Separate physician and pharmacy ownerships Competition problem Pharmaceutical companies and pharmacies may have an incentive to charge too high prices Common solution Regulate prices, including pharmacy gross margins

Broad geographic coverage policy Combine: relatively high regulated gross margins geographic entry restrictions to guarantee: sufficient entry in the unattractive areas without triggering excessive entry elsewhere Such policies have been followed in many European countries, including Belgium, France, Italy, etc.

The Establishment Act in Belgium In every municipality, the number of pharmacies is restricted based on population criteria. The population criteria are modified depending on -the number of pharmacists within a pharmacy -the distance between two pharmacies

The scope of our study Estimate an econometric model of entry and competition with geographic entry restrictions Evaluate the policy of relatively high regulated gross margins combined with tight entry restrictions. Is it indeed in the public interest (ensure sufficient geographical coverage) or is it rather in the pharmacies private interest?

General intuition of the entry model We observe the number of pharmacies (and physicians) per town We relate these to demographics, including population size. Interpretation of results -If population size needs to increase disproportionally to sustain an additional pharmacy, then entry implies enhanced competitive behavior. -If predicted number of sustainable firms would be higher than what is legally allowed, then there is room for additional entry.

VariableDescriptionMeanStd. D. # pharmaciesNumber of pharmacies # physiciansNumber of physicians ln(population)Logarithm of number of inhabitants % youngFraction of population, 17 years or younger % oldFraction of population, 65 years or older % foreignFraction of population with foreign nationality % unemployed Fraction of population between 17 and 65, that is unemployed FlandersDummy variable, 1 for region of Flanders mean incomeMean Income (/10,000) Source: NIS, Ecodata Demographics (NIS, Ecodata) Number of firms (RIZIV) Data on 847 small Belgian towns

Number of pharmacies Total Total, restricted entry Total, restricted entry (%) Total

Uncensored bivariate ordered probit Censored bivariate ordered probit General model with strategic complements Pharmacies’ payoff equation Constant (1.18) (3.40) (1.82) ln(population) 2.49 (0.06) 1.95 (0.12) 1.43 (0.13) % young (2.48) 0.73 (9.18) 0.22 (4.26) % old (2.43) (5.20) (3.54) % foreign (0.94) (0.96) (1.08) % unemployed 9.20 (2.22) (4.85) (4.40) Flanders (0.14) 0.13 (0.34) 0.11 (0.25) Income (0.14) (0.18) (0.19) 2.26 (0.11) 1.50 (0.18) 1.09 (0.23) 3.64 (0.13) 2.56 (0.20) 1.94 (0.30) 4.83 (0.15) 3.14 (0.22) 2.37 (0.35) (0.29)

Physicians’ payoff equation Constant (0.94) (1.12) (0.98) ln(population) 2.54 (0.07) 2.53 (0.08) 2.27 (0.07) % young 3.45 (2.08) 2.22 (2.25) 2.02 (2.15) % old 6.85 (1.84) 6.81 (1.90) 5.98 (1.89) % foreign (0.73) (0.69) (0.72) % unemployed 2.30 (1.83) 2.29 (1.98) 0.67 (1.89) Flanders (0.12) (0.13) (0.13) Income 0.32 (0.11) 0.32 (0.12) 0.37 (0.11) 1.30 (0.10) 1.32 (0.10) 1.23 (0.10) 2.34 (0.12) 2.36 (0.12) 2.27 (0.13) 2.99 (0.13) 3.09 (0.13) 2.91 (0.14) (0.19) (0.29) (0.83) (0.83) corr 0.32 (0.03) 0.05 (0.07) (0.09) Log Likelihood-2, , ,740.6

Summary of empirical findings Profitability is positively affected by -town size (population) -% old and % unemployed. Additional entry by pharmacies reduces profits, but this: -is only due to reduced sales; -is not due to enhanced competitive behavior. The entry restrictions are strongly binding, i.e. -at regulated profit margins more pharmacies want to enter.

What is the combined impact of -reducing the profit margins -loosening the entry restrictions on -total number of pharmacies -number of towns without pharmacy? This enables us to evaluate the public interest view of the current regulation, i.e. the guaranteeing of broad geographic coverage. Policy simulations

Net markup change No change-50% No change in entry restrictions Number of pharmacies Number of towns without pharmacies Full free entry in pharmacy market Number of pharmacies Number of towns without pharmacies

Additional policy experiments Introducing free entry and lowering regulated profit margins, such that the total number of pharmacies across all towns remains constant, leads to: -large markup reductions (tax savings) net margin drop by about 62% gross margin drop in the range of 10-18% -no significant loss in geographical coverage (-0.8%).  No public interest motivation for the current regime.

What next in Belgium and elsewhere? Gradual erosion of profits due to a ceiling on the regulated profit margins  Ultimately entry restrictions may become redundant. Can profit margins themselves be deregulated?  May require rethinking of reimbursement policies. What market failures motivate the many other restrictions in the establishment Acts?

What next in Europe? Similar or other restrictions apply in many other countries Urgent need for more independent economic research